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In vitro resistance of HIV-1 against high levels of HBY 097 ((S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-
dihydro-quinoxaline-2(1H)-thione) and other quinoxaline nonnucleoside reverse transcriptase inhibitors (NNRTIs) is charac-
terized by a specific amino acid substitution in the reverse transcriptase (RT), Gly190Glu. This change results in decreased RT
polymerase activity and in reduced growth properties of the corresponding viral variant. Here we show that the appearance of
the crippling mutation at codon 190 can be prevented by lowering the selective pressure exerted by HBY 097. Under low
selective pressure an accumulation of other NNRTI-specific mutations is observed. Up to five NNRTI-specific substitutions
were detected in some of these virus lineages. In addition, we report novel RT amino acid changes which were not observed
previously, including Val106Ile, Val106Leu, and Gly190Thr. HBY 097 selects for different mutational patterns under high
and low selective pressure conditions, respectively. Thus, the type of mutations which appear in HIV-infected patients
undergoing therapy may be determined by the levels of the selecting drug. q 1997 Academic Press
INTRODUCTION different experimental protocols to create resistant mu-
tants. Statistically significant evidence is presented prov-
HIV-1 resistance against nonnucleoside reverse tran-
ing the concept that lowering the selective pressure of
scriptase inhibitors (NNRTIs) is mediated through muta-
HBY 097 results in different viral genotypes compared to
tions affecting the hydrophobic NNRTI binding pocket
those found under high selective pressure conditions.
within the polymerase domain of the p66 subunit (Tantillo
Our results may help to explain the appearance of
et al., 1994; De Clercq, 1995; Schinazi et al., 1996).
different resistant mutants detected with HBY 097 or
Though nucleoside RT inhibitors (NRTIs) have different
other inhibitors under in vivo conditions.
molecular target sites at the same enzyme, the resis-
tance profiles of these two classes of drugs have been MATERIALS AND METHODS
shown to interact. For example, it has been shown that
Inhibitors of the HIV reverse transcriptasethe type of pol gene mutations which appear with NNRTIs
is influenced by preexisting NRTI resistance mutations: HBY 097 ((S)-4-isopropoxycarbonyl-6-methoxy-3-(methyl-
(/)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2- thiomethyl)-3,4-dihydro-quinoxaline-2(1H)-thione) and S-
butenyl)imidazo [4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione 2720 (6-chloro-3,3-dimethyl-4-(isopropenyloxycarbonyl)-
(TIBO R82913) and nevirapine select mainly for the 3,4-dihydroquinoxaline-2(1H)-thione) were synthesized as
Tyr181Cys substitution both in vitro and in vivo. In con- described (Kleim et al., 1993, 1995). Zidovudine (3*-deoxy-
trast, the presence of a zidovudine-resistant background 3*-azidothymidine; AZT) was obtained from Burroughs
causes the frequent appearance of Lys103Asn, Val106Ala, Wellcome (Research Triangle Park, NC). Delavirdine (1-
Gly190Ala, and other substitutions affecting the NNRTI (5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-(3-1-
binding pocket of the RT when the same drugs are used methylethyl - aminopyridinyl) - piperazine; U - 90152) and
(Richman et al., 1991, 1994; Larder, 1992). nevirapine (6,11-dihydro-11-cyclopropyl-4-methyldipyrido-
Little is known about the influence of other parameters (1,4)diazepin-6-one; BI-RG-587) were prepared according
related to the selective pressure of a certain drug (or to published methods (Hargrave et al., 1991; Romero et
drug combination) on the qualitative generation of viral al., 1993).
resistance. We describe here the results of comparative
Selection conditions for the generation of HBY 097-in vitro selection experiments with the quinoxaline NNRTI
resistant HIV-1 variantsHBY 097 (Kleim et al., 1995; Fig. 1), applying defined
The HIV-1MN laboratory strain was used and viruses
were propagated on H9 cells as described (Kleim et al.,1 To whom reprint requests should be addressed.
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dideoxy chain termination sequencing reaction. Primers
RT1SEQ2F and RT8KF (Kleim et al., 1995) allowed the
determination of HIV-1 provirus sequences correspond-
ing to RT amino acids 35–242. Analysis of the reactions
was performed with the aid of an ALF automated DNA
sequencer (Pharmacia).
Phenotypic resistance of late passage viruses from
individual lineages against HBY 097 and four other RT
inhibitors was done by evaluation of the 50% inhibitory
concentrations (IC50s): 1 1 106 cells were infected for 30
min with HIV-1MN or one of the described group A/B
variants at 2–41 105 tissue culture infective units (TCIU).
Supernatants were then removed and infected cells were
FIG. 1. HBY 097 ((S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio- transferred to 24-well plates (Greiner; 2.5 1 105 cells/
methyl)-3,4-dihydro-quinoxaline-2(1H)-thione). ml/well). Drugs in serial fivefold dilutions were added
immediately, followed by 72 hr of incubation at 377 in a
5% CO2 humid atmosphere. For the calculation of IC501995). These reagents were obtained through the AIDS
values, the p24 antigen concentrations in the culture su-Research and Reference Reagent Program, AIDS Pro-
pernatants were measured by an antigen capture assaygram, National Institute of Allergy and Infectious Dis-
(Organon Teknika).eases, Bethesda, MD. Virus lineages were divided in two
categories: group A mutants (high selective pressure; 7 RESULTS
individual lineages) were obtained by raising the HBY
Generation of highly resistant mutant viruses using097 concentration by a factor of 4–5 with every subculti-
defined different experimental proceduresvation step. The amount of drug present in the passage
We examined the development of in vitro resistance1 culture medium was 0.5 ng/ml, and the last cultures
against the NNRTI HBY 097 under different selectiveanalyzed contained 10,000 ng/ml of HBY 097. Group B
pressure conditions. The aim was to find out whethermutants (low selective pressure; 12 different lineages)
the HIV-1MN parental strain would genotypically evolvewere treated in the same way, except that the concentra-
in a different way in those cell cultures, allowing the virustion of drug was raised only 2- to 2.5-fold with every
to adapt more slowly to higher concentrations of thesubsequent passage. Within group B the initial and final
inhibitor. Virus lineages were divided into two categories:compound concentrations were 0.2, 0.4, or 0.5 ng/ml and
group A was characterized by high selective pressure;10,000 or 20,000 ng/ml, respectively.
i.e., the concentration of HBY 097 was raised by a factor
of five with every new subcultivation step. In group B,Genotypic and phenotypic analyses of HIV-1MN group
the factor was two, resulting in low selective pressureA versus group B variants
conditions.
The appearance of RT gene mutations was monitored In cultures of both group A (A1–A3, A5, A7) and group
at different time points for all virus lineages from group B (B7–B10, B12), it was necessary to use the same
A and group B: Total DNA from infected H9 cells was amount of HBY 097 at two or more subsequent passages,
purified using a silica-membrane-based spin column sys- since no virus replication was observed in the corre-
tem (Qiagen). DNA was eluted in 10 mM Tris–HCl, 1 mM sponding wells at a given drug concentration. However,
EDTA, pH 8.0. For a first PCR analysis 0.5 mg of DNA once a limit of 50 ng/ml HBY 097 was reached, it was
was used with 10 pmol/50 ml of primers JA99 and RIT137 easily possible to proceed to the next dose level in all
(Albert et al., 1994), respectively. Reaction conditions of the 19 lineages analyzed. Under lowered selective
were 3 min, 947; 35 to 50 cycles for 30 sec, 967; 30 sec, pressure (group B) this 50 ng/ml threshold was reached
607; and 60 sec, 727 in 0.2 mM each dNTP, 10 mM Tris – at passage 9 in most cultures, whereas under high selec-
HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2 , and 2 units/50 tive pressure (group A) the majority of cultures arrived
ml of Taq polymerase (Boehringer Mannheim). at the same concentration of HBY 097 after five subcultiv-
An aliquot of the first PCR was used for a nested ampli- ations. The final concentrations were 10,000 or 20,000
fication with primers JA100 and RIT138 (Albert et al., 1994; ng/ml, equaling up to 40,000-fold the initial amount of
Kleim et al., 1995) using the same protocol as above, compound used in the first passage.
omitting the initial denaturation step. The biotinylated
Evaluation of genotypic changes in RT genes of groupDNA strand of the 817-bp product was first separated
A and group B mutantsfrom the unlabeled complementary strand using streptav-
idin-coated magnetic beads (Dynal) and the single- In order to determine the lower limit of detection of
variants at a given nucleotide position, PCR productsstranded DNA was then served as a template for the
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TABLE 1
Genotypic Analyses of Group A Strains (High Selective Pressure) versus Group B Lineages (Low Selective Pressure)
Strain Passage No., [HBY 097 (ng/ml)] genotypea
Group A viruses
A1 1, 0.5 c 5, 2.5 c 10, 5,000 c 15, 20,000 c 20
wt Gly190Ala/wt Leu100Ile/wt, Gly190Glu Gly190Glu
Gly190GLu/Ala
A2 1,0.5 c 5, 2.5 c 10, 20,000 c 15 c 20
wt Val106Ala/wt, Leu74Val, Leu74Val, Leu74Val,
Tyr181Cys/wt, Gly190Glu Gly190Glu Gly190Glu
Tyr188His/wt
A3 1, 0.5 c 5, 50 c 10, 20,000 c 15 c 20
wt Val106Ile, Gly190Glu Leu74Val/wt, Leu74Val/wt,
Tyr181Cys Gly190Glu Gly190Glu
A4 1, 0.5 c 5, 250 c 10, 20,000 c 15 c 20
wt Leu100Ile, Leu100Ile/wt, Leu74Val/wt, Leu74Val/wt,
Tyr188His/wt, Gly190Glu/Ala/ Leu100Ile/wt, Leu100Ile,
Gly190Ala Val Gly190Glu/Ala Val106Ala,
Gly190Glu/Ala,
Phe227Leu
A5 1, 0.5 c 5, 10 c 10, 20,000 c 15 c 20
wt Leu100Ile/wt, Gly190Glu Gly190Glu Valy75Leu/wt,
Val106Ile/wt, Gly190Glu
Tyr181Cys/wt
A6 1, 0.5 c 5, — c 10, 5,000 c 15, 20,000 c 20
wt ND Gly190Val, Gly190GlulVal, Leu74Val/wt,
Glu194Gln/wtb Glu194GLn/wt,b Gly190GlulVal,
Lys219Glu/wtc Glu194Gln/wt,b
Lys219Gluc
A7 6, 60 c 11, 20,000 ng/ml c 15 c 20 c 30
ND Gly190Glu Val106Leu/wt, Val106Leu, Val106Leu,
Tyr181Cys, Tyr181Cys, Tyr181Cys,
Tyr188His/Leu, Tyr188Leu Tyr188Leu
Gly190Glu/wt
Group B viruses
B1 1, 0.2 c 5, 4 c 10, 200 c 15, 10,000 c 20
wt wt Gly190Glu Gly190Glu, Gly190Glu
Val179Gly/wtb Val179Glyb
B2 1, 0.2 c 5, 4 c 10, 200 c 15, 10,000 c 20
wt Leu100Ile/wt Leu100Ile, Leu100Ile, Leu100Ile,
Tyr181lle Tyr181Ile Tyr181Ile,
Gly190Ala
B3 1, 0.2 c 5, 4 c 10, 200 c 15, 10,000 c 20
wt Leu100Ile/wt Leu100Ile/wt, Leu100Ile/wt, Leu100Ile,
Lys103Asn, Lys103Asn, Lys103Asn,
Tyr181Cys/wt, Tyr181Cys, Tyr181Cys/wt,
Gly190Ala/wt Gly190Ala/wt Val189Ile/wt,
Gly190Ala
B4 1, 0.2 c 5, 4 c 1, 200 c 15, 10,000 c 20
wt Leu100Ile/wt Leu100Ile/wt, Leu100Ile, Leu100Ile,
Lys103Asn/wt, Lys103Asn, Lys103Asn,
Tyr181Cys/wt, Tyr181Cys/wt, Tyr181Cys/wt,
Gly190Ala/wt Tyr188Phe/Leu/His Tyr188Leu/His,
Gly190Ala/wt
B5 1, 0.2 c 5, 4 c 10, 200 c 15, 10,000 c 20
wt Leu100Ile/wt Leu100Ile/wt, Leu100Ile/wt, Leu100Ile,
Lys103Asn, Lys103Asn, Lys103Asn,
Tyr181Cys/wt Tyr181Cys/wt Tyr181Cys,
Gly190Ala/wt
B6 1, 0.2 c 5, 4 c 10, 200 c 15, 10,000 c 20
wt wt Leu100Ile/wt, Leu100Ile/wt, Leu100Ile/wt,
Gly190Ala Gly190Glu/Ala Gly190Glu/Ala
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TABLE 1—Continued
Strain Passage No., [HBY 097 (ng/ml)] genotypea
B7 6, 16 c 11, 500 c 15, 8,000 c 20, 20,000 c 30
Gly190Ala ND Leu74Val/wt, Leu74val, Leu74Val,
Leu100Ile, Leu100Ile, Leu100Ile,
Gly190Thr/Ala Gly190Thr Gly190Thr
B8 5, 2 c 10, 60 c 15, 2,000 c 31, 20,000 c 40
Tyr181Cys/wt Lys103Asn, Lys103Asn, Lys101Ile, Lys101Ile,
Tyr181Cys Tyr181Cys Lys103Asn, Lys103Asn,
Tyr181Cys, Tyr181Cys,
Gly190Ala Gly190Ala
B9 5, 4 c 10,120 c 15, 4,000 c 31, 20,000 c 40
Gly190Ala Leu100Ile, Leu100Ile, Leu100Ile, Leu100Ile,
Gly190Ala Val106Ala/wt Val106Ala, Val106Ala,
Gly190Ala Gly190Ala Gly190Ala
B10 5, 8 c 10, 240 c 15, 8,000 c 31, 20,000 c 40
Leu100Ile/wt, ND Leu100Ile, Leu100Ile, Asp86Asn,b
Tyr181Cys/wt Thyr181Cys, Val106Ile, Leu100Ile,
Tyr188His Tyr181Cys, Val106Ile,
Tyr188Leu Tyr181Cys,
Tyr188Leu
B11 5, 16 c 10, 500 c 15, 16,000 c 31 c 40
Leu100Ile Leu100Ile, Leu100Ile, Leu74Ile, Leu74Ile,
Val106Ala Val106Ala, Leu100Ile, Leu100Ile,
Pro225His Lys103Asn, Lys103Asn,
Val106Ala/wt, Tyr181Ile/
Pro225His Asn/Lys
Pro225His
B12 5, 2 c 10, 60 c 15, 2,000 c 31, 20,000 c 40
wt Lys103Arg/wt Leu100Ile/wt, Leu100Ile, Leu100Ile,
Tyr181Ile, Tyr181Ile, Tyr181Ile,
Gly190Ala/wt Gly190Ala Gly190Ala
Note. Slashes indicate mixed populations apparent at a given codon position. ND, not determined; wt, wild type.
a For better clarity, drug concentrations are not indicated once 10,000 ng/ml are reached. The Gly190Glu change is printed in italics.
b Asp86Asn, Val179Gly, and Glu194Gln have not been reported to be associated with drug resistance (Schinazi et al. (1996); the significance of
these changes is not clear.
c Lys219Glu is a substitution originally observed in zidovudine-resistance HIV-1 RT (Larder et al., 1991).
derived from HIV-1MN and RT Gly190Glu mutant virus present. The crippling Gly190Glu mutant RT was de-
tected in all lineages of the high selective pressure groupwere mixed at different ratios and submitted to sequenc-
ing reactions. The limit of detectability of the G r A A, but the same change was noted in only 2/12 of the
RT genes derived from low selective pressure virusestransition was found to be at a proportion of 0.875:0.125
(wt:Gly190Glu; data not shown). (group B). This difference is highly statistically significant
(P  0.001, x2 test). In group B, an accumulation of otherEach of the individual lineages of both groups was
analyzed for resistance-conferring mutations for at least NNRTI-specific mutations was observed, also resulting
in high-level HBY 097 resistance: a total of five differentfour different time points (passages) during the dose es-
calation procedure. A summary of the results of the positions relevant for NNRTI resistance were mutant in
strains B3 and B4. Secondary changes at NRTI resis-comprehensive mutational analyses is given in Tables 1
and 2. tance positions were identified in 5/7 strains of group A
and in 2/12 strains belonging to group B (P  0.05).All lineages in both groups displayed the parental ge-
notype at HBY 097 concentrations below 2 ng/ml. At Novel mutations at sites with defined importance for RT
inhibitor resistance are Val106Ile, Val106Leu, Gly190Thr,higher drug levels, alterations at various positions ap-
peared, with Leu100Ile being the most abundant change and Gly190Val. The Val106Leu substitution was present
only in lineage (A7) where a replacement of Gly190Glu(13/19 lineages). Above 60 ng/ml of HBY 097, either the
codons of two amino acids changed in the RT gene of was evident: a variant carrying a triple mutant RT had
completely displaced Gly190Glu at passage 20.each of the strains or the Gly190Glu substitution was
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TABLE 2
Quantitative Evaluation of Individual Amino Acid Changs Observed in Both Groups
Resistance-conferring mtuations
HIV-1RT Parental
amino acid No. phenotype Mutant 1 Mutant 2 Mutant 3 Mutant 4
100 Leu Ile (3/10)
101 Lys Ile (0/1)
103 Lys Asn (0/5) Arg (0/1)
106 Val Ala (2/2) Ilea (2/1) Leua (1/0)
179 Val Glya (0/1)
181 Tyr Cys (4/5) Ile (0/3) Lysa,b (0/1) Asna,b (0/1)
188 Tyr His (3/2) Leu (1/2) Phea (0/1)
189 Val Ile (0/1)
190 Gly Ala (2/9) Glu (7/2) Val (1/0) Thra (0/1)
225 Pro Hisa (0/1)
Secondary changes
74 Leu Val (3/1) Ile (0/1)
75 Val Leu (1/0)
219 Lys Glu (1/0)
Note. Each mutant amino acid is counted once per individual lineage. Numbers in parentheses, number of appearances in group A/group B.
a Change occurred at a position relevant for NNRTI resistance; specific influence of this particular amino acid not yet determined.
b Tyr181Lys/Asn codons were detected as possible genotypes in only one mixed population (B11).
Phenotypic resistance of individual group A and A transition, appeared preferentially under high selective
pressure. In contrast, attenuation of the selective pres-group B viral variants
sure exerted by the inhibitor yielded multiple mutations
Late passage viruses from different lineages of both at various codons. Interestingly, Gly190Ala—which does
groups, carrying up to four mutations in their RT genes, not confer complete resistance to HBY 097 and retains
were tested for their susceptibilities to inhibition by vari- wt level polymerase activity—was also observed more
ous RT inhibitors (Table 3). All of the NNRTIs tested were frequently in group B. (ii) Secondary mutations affecting
completely inactive against mutants A1, A2, B8, and B9 codons relevant for NRTI resistance were previously de-
(i.e., lost up to 1670-fold of inhibitory potency compared scribed to appear with HBY 097 in dose escalation exper-
to activities seen with the parental virus). iments, and the resulting amino acid changes have been
partly demonstrated to have compensatory effects on RT
polymerase activity (Kleim et al., 1996). These mutationsDISCUSSION
were more likely to show up under high selective pres-
sure conditions.In this study, we describe for the first time the defined
Winslow et al. (1996) described a limited accumulationmanipulation of HIV-1 genotypes using an inhibitor of
of mutations with the NNRTI DMP 266. Consistent withHIV-1 replication. Resistance against the quinoxaline
our data, there were different patterns of mutations foundHBY 097 was accomplished by two general pathways in
with two different experimental settings. However, morea well-characterized in vitro system, using a permanent
than one parameter was varied (i.e., different cell typescell line and a laboratory strain of HIV-1. Alternative se-
and different selection procedure), and the data werelective pressure conditions applied result in two different
lacking statistical power. It is important to note that theways followed by HIV-1MN to become resistant against
stepwise acquisition of mutations in the RT genes of HBYthe quinoxaline derivative. These are characterized by
097-treated HIV-1 leads to increasing resistance to thedifferent raise factors of the drug concentration in the
drug. Most of the mutations found (i.e., Leu100Ile, Lys-virus cultures, resulting in high (group A) and low (group
103Asn, Val106Ala, Tyr181Cys, Gly190Ala) were pre-B) selective pressure. Though viral variants of both
viously tested for their ability to confer resistance to quin-groups acquired indistinguishable high-level NNRTI re-
oxaline class NNRTIs. Present as single mutants, nonesistance (Table 3), statistically significant differences
of these changes could be demonstrated to cause high-were noted with respect to the mutations which led to
level resistance (Balzarini et al., 1994, 1996a; Kleim et al.,the observed phenotypes (Tables 1, 2): (i) The crippling
Gly190Glu alteration, which is derived from a single G r 1994, 1995). However, when changes such as Leu100Ile/
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TABLE 3
Sensitivity of Late Passage Viruses from Different Group A and Group B Strains to HBY 097 and Other Reverse Transcriptase Inhibitors
Compound, IC50 (ng/ml)
Virus HBY 097 S-2720 Nevirapine Delavirdine Zidovudine
HIV-1MN 7 6 90 180 50
A1 10000 10000 10000 10000 50
(Gly190Glu)
A2 10000 1000 10000 8700 50
(Leu 74Val,
Gly190Glu)
B8 10000 10000 10000 10000 50
(Lys101Ile, Lys103Asn,
Ty181Cys, Gly190Ala)
B9 10000 10000 10000 10000 30
(Leu100Ile, Val106Ala,
Gly190Ala)
a Strain designations correspond to labelling in Table 1.
Val108Ile/Tyr181Ile or Tyr181Cys/Tyr188Leu/Gly190Ala/ In conclusion, pharmacokinetic properties are critical
Met230Leu were expressed as multiple mutant enzymes parameters for the type of mutations which will appear
in Escherichia coli, the derived proteins were found to with HBY 097 and other drugs during therapy of HIV
be highly resistant to inhibition by quinoxalines and other infection. In that way, selective pressure has to be viewed
NNRTIs. In addition, these enzymes retained wild-type as another determinant of qualitative resistance develop-
level RNA-dependent DNA polymerase activities in vitro ment in addition to factors such as genetic background or
(Kleim et al., 1995; and data not shown). drug combinations. As part of novel combination therapy
In contrast, NNRTI resistance mediated by the regimens, NNRTIs such as HBY 097 can be useful to
Gly190Glu change is accompanied by a weak RT poly- slow down or even suppress the development of viral
merase activity and retarded in vitro growth properties resistance (Balzarini et al., 1996b; Myers et al., 1996).
of the corresponding mutant virus (Kleim et al., 1993,
1994; Olmsted et al., 1996). Glu190—as observed in ACKNOWLEDGMENTS
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group B. Taken together, these data strongly suggest that
the described accumulation phenomenon represents an
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